Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland; Heart Center and Gene Therapy Unit, Kuopio University Hospital, PO Box 1777, 70211 Kuopio, Finland.
Trends Endocrinol Metab. 2017 Apr;28(4):285-296. doi: 10.1016/j.tem.2016.12.002. Epub 2017 Jan 10.
Recent progress in lymphatic vessel biology and in novel imaging techniques has established the importance of the lymphatic vasculature as part of the cardiovascular system. The lymphatic vessel network regulates many physiological processes important for heart function such as fluid balance, transport of extravasated proteins, and trafficking of immune cells. Therefore, lymphangiogenic therapy could be beneficial in the treatment of cardiovascular diseases, for example by improving reverse cholesterol transport (RCT) from atherosclerotic lesions or by resolving edema and fibrosis after myocardial infarction. In this review we first describe recent findings on the development and function of cardiac lymphatic vessels, and subsequently focus on the prospects of pro- and anti-lymphangiogenic therapies in cardiovascular diseases.
近年来淋巴管生物学和新型成像技术的进展确立了淋巴血管系统作为心血管系统一部分的重要性。淋巴血管网络调节着许多对心脏功能重要的生理过程，如液体平衡、渗出蛋白的运输和免疫细胞的运输。因此，淋巴管生成治疗可能有益于心血管疾病的治疗，例如通过改善动脉粥样硬化病变中的逆向胆固醇转运 (RCT) 或通过解决心肌梗死后的水肿和纤维化。在这篇综述中，我们首先描述了心脏淋巴管的发育和功能的最新发现，随后重点介绍了促淋巴管生成和抗淋巴管生成治疗在心血管疾病中的前景。
